Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Lusaris Therapeutics is raising $60,000,000.00 in new funding. Sources indicate as part of senior management Interim Chief Executive Officer, Andrew Levin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lusaris Therapeutics

Lusaris is a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. Our lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic in development for treatment-resistant depression and other neuropsychiatric conditions. In addition to LSR-1019, our pipeline includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions including migraine and cluster headache.

To learn more about Lusaris Therapeutics, visit http://LusarisTx.com/

Contact:
Andrew Levin, Interim Chief Executive Officer
617-778-2500

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved